Intrexon (NYSE:XON) had its price target upped by JMP Securities from $42.00 to $43.00 in a research note published on Wednesday morning. They currently have a market outperform rating on the biotechnology company’s stock.
A number of other brokerages have also issued reports on XON. ValuEngine raised Intrexon from a strong sell rating to a sell rating in a research report on Monday, August 20th. Zacks Investment Research raised Intrexon from a hold rating to a buy rating and set a $16.00 target price on the stock in a research report on Thursday, August 16th. Bank of America lowered Intrexon from a neutral rating to an underperform rating and set a $12.00 target price on the stock. in a research report on Monday, July 16th. Finally, Stifel Nicolaus initiated coverage on Intrexon in a research report on Tuesday, July 17th. They set a buy rating and a $72.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Intrexon has an average rating of Hold and an average target price of $29.67.
XON opened at $15.12 on Wednesday. Intrexon has a one year low of $10.26 and a one year high of $20.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.78. The firm has a market capitalization of $2.47 billion, a PE ratio of -16.43 and a beta of 1.09.
Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The firm had revenue of $45.30 million during the quarter, compared to the consensus estimate of $51.70 million. During the same period in the prior year, the firm posted ($0.16) EPS. On average, research analysts forecast that Intrexon will post -0.79 EPS for the current year.
In other news, insider Helen Sabzevari sold 8,402 shares of the business’s stock in a transaction on Wednesday, July 18th. The stock was sold at an average price of $14.54, for a total transaction of $122,165.08. Following the sale, the insider now directly owns 25,000 shares of the company’s stock, valued at $363,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 48.20% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in XON. BB&T Securities LLC acquired a new stake in shares of Intrexon during the second quarter worth $175,000. Chessman Wealth Strategies RIA acquired a new position in Intrexon during the second quarter valued at $205,000. Verition Fund Management LLC acquired a new position in Intrexon during the first quarter valued at $223,000. Bayesian Capital Management LP acquired a new position in Intrexon during the first quarter valued at $236,000. Finally, Opus Point Partners Management LLC raised its position in Intrexon by 29.9% during the first quarter. Opus Point Partners Management LLC now owns 18,478 shares of the biotechnology company’s stock valued at $283,000 after buying an additional 4,257 shares during the period. 84.92% of the stock is currently owned by institutional investors.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Recommended Story: Return on Investment (ROI)
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.